Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Associates of Cape Cod, Inc.
FDA clears new fungal infection diagnostic test
June 26th, 2004
Associates of Cape Cod, Inc., (ACC) announced that the U.S. Food and Drug Administration has cleared Glucatell, a serological assay that is intended for the qualitative detection of beta-glucan in the serum of patients with symptoms of, or medical conditions predisposing the patient to, invasive fungal infection and as an aid in the diagnosis of deep seated mycoses and fungemias. ACC is a manufacturer of endotoxin and beta-glucan detection products and a major supplier to the pharmaceutical and medical device industries. Glucatell, a serum test, measures (1,3)-beta-D-glucan, a fungal wall compound that is shed into the blood during fungal infections....
Source: Law & Health Weekly (2004-06-26)
|
